The Impact of Obesity on the Incidence of Type 2 Diabetes Among Women With Polycystic Ovary Syndrome
The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The nature of the independent relationship between polycystic ovary syndrome (PCOS) and type 2 diabetes remains unclear. Few studies have aimed to clarify this relationship independent of obesity in longitudinal population-based cohorts. RESEARCH DESIGN AND METHODS: We used the Australian Longitudinal Study on Women’s Health (ALSWH) (2000–2015) database to estimate nationwide incidence rates and predictors of type 2 diabetes among women aged 18–42 using person-time and survival analysis. RESULTS: Over a follow-up of 1,919 person-years (PYs), 186 women developed type 2 diabetes. The incidence rate was 4.19/1,000 PYs and 1.02/1,000 PYs (P < 0.001) in PCOS and control subjects. On subgroup analyses across healthy-weight, overweight, and obese categories of women, the incidence rates for type 2 diabetes were 3.21, 4.67, and 8.80, whereas incidence rate ratios were 4.68, 3.52, and 2.36 (P < 0.005) in PCOS versus age-matched control subjects. PCOS was one of the most influential predictors for type 2 diabetes in the entire cohort (hazard ratio 3.23, 95% CI 2.07–5.05, P < 0.001) adjusting for BMI, education, area of residence, and family history of type 2 diabetes. CONCLUSIONS: Women with PCOS are at an increased risk of type 2 diabetes, irrespective of age and BMI. The incidence of type 2 diabetes increases substantially with increasing obesity; yet, PCOS adds a greater relative risk in lean women. Based on the overall moderate absolute clinical risk demonstrated here, guideline recommendations suggest type 2 diabetes screening every 1–3 years in all women with PCOS, across BMI categories and age ranges, with frequency influenced by additional type 2 diabetes risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
March, W. A., Moore, V. M., Willson, K. J., Phillips, D. I. W., Norman, R. J., & Davies, M. J. (2010) · Human Reproduction · doi:10.1093/humrep/dep399 · Cited by 1,799
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · cited 1×
“Our findings are consistent with meta-analyses (8) and smaller hospital-based studies (8,21,24).”
ResultPrevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 1×
“Previous studies have been inconclusive about the independent effect of PCOS on type 2 diabetes, with methodological limitations including small sample sizes (8,9,11), use of”
Standards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/er.18.6.774 · Cited by 1,155
Moran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq001 · Cited by 1,108
Self-citation
Research works printed but not linked: 1
- Polycystic Australian Alliance, 2011, Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome
Cited by
Joham, A. E., Norman, R. J., Stener-Victorin, E., Legro, R. S., Franks, S., Moran, L. J., Boyle, J., & Teede, H. J. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00163-2 · Cited by 838
Self-citationOsibogun, O., Ogunmoroti, O., & Michos, E. D. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.08.010 · Cited by 423
Diabetes: A metabolic and reproductive disorder in women
Thong, E. P., Codner, E., Laven, J. S. E., & Teede, H. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30345-6 · Cited by 242
Self-citationPolycystic ovary syndrome and risk of type 2 diabetes, coronary heart disease, and stroke
Zhu, T., Cui, J., & Goodarzi, M. O. (2021) · Diabetes · doi:10.2337/db20-0800 · Cited by 226
“However, some studies that did attempt to match for or statistically adjust for BMI reported positive association between PCOS and diabetes (25,31,32).”
ResultInsulin resistance and PCOS: chicken or egg?
Moghetti, P., & Tosi, F. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01351-0 · Cited by 209
Effect of Diet on Insulin Resistance in Polycystic Ovary Syndrome
Shang, Y., Zhou, H., Hu, M., & Feng, H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa425 · Cited by 171
ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents
Shah, A. S., Zeitler, P. S., Wong, J., Pena, A. S., Wicklow, B., Arslanian, S., Chang, N., Fu, J., Dabadghao, P., Pinhas‐Hamiel, O., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13409 · Cited by 170
“8/1000 person years in 1136 young women aged 15–44 years with PCOS with and without obesity.(224) The TODAY study reported that girls with T2D who were more than 1 year post-menarche have a higher frequency of irregular menstrual cycles (three or fewer periods in the previous 6 months) compared to previous data in hea…”
ResultTan, W., Dai, F., Yang, D., Deng, Z., Gu, R., Zhao, X., & Cheng, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967151 · Cited by 163
Witchel, S. F., Teede, H. J., & Peña, A. S. (2019) · Pediatric Research · doi:10.1038/s41390-019-0615-1 · Cited by 156
“After adjusting for BMI, education, and family history of T2DM, women with PCOS have an increased risk to develop T2DM at an earlier age; this risk is exacerbated by obesity.(63,64) Hence, glycemic status should be evaluated in all women at the time of PCOS diagnosis and reviewed regularly according to the presence of…”
BackgroundSelf-citationDi Lorenzo, M., Cacciapuoti, N., Lonardo, M. S., Nasti, G., Gautiero, C., Belfiore, A., Guida, B., & Chiurazzi, M. (2023) · Current Nutrition Reports · doi:10.1007/s13668-023-00479-8 · Cited by 108
Quercetin and polycystic ovary syndrome, current evidence and future directions: a systematic review
Tabrizi, F. P. F., Hajizadeh‐Sharafabad, F., Vaezi, M., Vayghan, H. J., Alizadeh, M., & Maleki, V. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-0616-z · Cited by 112
“Although the definite etiology of PCOS remains unclear, complex interactions between genetic, behavioral, and environmental factors play critical roles in the development of PCOS and subsequent therapeutic options [10].”
BackgroundThe Influence of Metabolic Factors and Diet on Fertility
Łakoma, K., Kukharuk, O., & Śliż, D. (2023) · Nutrients · doi:10.3390/nu15051180 · Cited by 134
“As obesity increases, the incidence of type 2 diabetes is increasing significantly; however, PCOS increases the relative risk in thin women [36].”
BackgroundShen, H., Xu, X. L., & Li, X. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-020-00684-y · Cited by 87
Samarasinghe, S., Leca, B. M., Alabdulkader, S., Dimitriadis, G. K., Davasgaium, A., Thadani, P., Parry, K., Luli, M., O'Donnell, K., Johnson, B., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00538-5 · Cited by 99
“Women with PCOS are at higher risk of developing type 2 diabetes, 32 dyslipidaemia, 33 hypertension, 34 and probably cardiovascular disease 35 compared with age-matched and BMI-matched women without PCOS.”
Mendelian randomization analyses for PCOS: evidence, opportunities, and challenges
Wang, C., Wu, W., Yang, H., Ye, Z., Zhao, Y., Liu, J., & Mu, L. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.01.005 · Cited by 81
Beyene, H. B., Giles, C., Huynh, K., Wang, T., Cinel, M. A., Mellett, N. A., Olshansky, G., Meikle, T. G., Watts, G. F., Hung, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41963-7 · Cited by 93
Acupuncture versus sham acupuncture for simple obesity: a systematic review and meta-analysis
Zhong, Y., Luo, X., Chen, Y., Lai, D., Lu, W., Shang, Y.-N., Zhang, L., & Zhou, H. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137221 · Cited by 68
Challenges in diagnosis and understanding of natural history of polycystic ovary syndrome
Joham, A. E., Piltonen, T., Lujan, M. E., Kiconco, S., & Tay, C. T. (2022) · Clinical Endocrinology · doi:10.1111/cen.14757 · Cited by 80
Self-citationShang, Y., Zhou, H., He, R., & Lu, W. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735954 · Cited by 61
“Hence, it is warranted to define the effectiveness of diet in promoting reproductive health among women with PCOS, in order to provide appropriate dietary advice for clinical practice.”
BackgroundInfluentialHigher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome
Persson, S., Elenis, E., Türkmen, Ş., Kramer, M. S., Yong, E., & Poromaa, I. S. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.04.018 · Cited by 66
Joham, A. E., Kakoly, N. S., Teede, H. J., & Earnest, A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab134 · Cited by 59
Self-citationJensterle, M., Kravos, N. A., Ferjan, S., Goričar, K., Dolžan, V., & Janež, A. (2020) · Endocrine Connections · doi:10.1530/ec-19-0449 · Cited by 54
“The most recent Australian Longitudinal Study on Women’s Health database reported that women with PCOS are at an increased risk of T2D, irrespective of age and BMI (2).”
BackgroundDevelopment of type 2 diabetes in adolescent girls with polycystic ovary syndrome and obesity
Hudnut‐Beumler, J., Kaar, J. L., Taylor, A., Kelsey, M. M., Nadeau, K. J., Zeitler, P., Snell‐Bergeon, J., Pyle, L., & Cree‐Green, M. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13206 · Cited by 46
“8/1000 PYs in obese women.(12) Current screening recommendations acknowledge the increased risk of diabetes in women with PCOS and thus recommend universal screenings for T2D in women with PCOS every 1– 3 years.”
BackgroundCardiometabolic Risk in Polycystic Ovary Syndrome
Cooney, L. G., & Dokras, A. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.11.001 · Cited by 44
“Although cross-sectional studies do not show an increased risk of DM independent of BMI, multiple larger population-based and longitudinal studies have demonstrated an increased risk of DM even after adjusting for BMI.(19,22,23,27) Future studies should focus on evaluation of the risk of IGT/DM in adolescents.”
BackgroundInfluentialWang, R., Gu, Z., Wang, Y., Yin, X., Liu, W., Chen, W., Huang, Y., Wu, J., Yang, S., Feng, L., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202206670 · Cited by 47
Sabag, A., Patten, R. K., Moreno‐Asso, A., Colombo, G. E., Bouzo, X. D., Moran, L., Harrison, C. L., Kazemi, M., Mousa, A., Tay, C. T., et al. (2024) · Journal of science and medicine in sport · doi:10.1016/j.jsams.2024.05.015 · Cited by 66
Self-citationAnagnostis, P. G., Paparodis, R. D., Bosdou, J. Κ., Bothou, C., Μacut, D., Goulis, D. G., & Livadas, S. (2021) · Endocrine · doi:10.1007/s12020-021-02801-2 · Cited by 52
Ryu, K.-J., Kim, M. S., Kim, H. K., Kim, Y. J., Yi, K. W., Shin, J., Hur, J. Y., Kim, T., & Park, H. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.12.018 · Cited by 49
Prevalence of polycystic ovary syndrome: a global and regional systematic review and meta-analysis
Neven, A. C. H., Forslund, M., Ranasinha, S., Sethi, P., Dhungana, R. R., Mousa, A., Tay, C. T., Teede, H. J., & Boyle, J. (2026) · Human Reproduction Update · doi:10.1093/humupd/dmaf030 · Cited by 92
Self-citationRani, R., Hajam, Y. A., Kumar, R., Bhat, R. A., Rai, S., & Rather, M. A. (2021) · Phytomedicine Plus · doi:10.1016/j.phyplu.2021.100161 · Cited by 50
Lin, H., Liu, M., Zhong, D., Ng, E. H. Y., Liu, J., Li, J., Shi, Y., Zhang, C., Wen, X., Mai, Z., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.709674 · Cited by 47
The challenges of assessing adiposity in a clinical setting
Börgeson, E., Tavajoh, S., Lange, S., & Jessen, N. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01012-9 · Cited by 47
“…oestrogen and its receptor are a key component to sex differences in adipose distribution, and women with high testosterone levels (due to polycystic ovary syndrome) are at an increased risk of developing T2DM, compared with women with normal levels of testosterone, irrespective of age and BMI 45 .”
Kazemi, M., Lalooha, F., Nooshabadi, M. R., Dashti, F., Kavianpour, M., & Haghighian, H. K. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00849-2 · Cited by 42
Long, C., Feng, H., Duan, W., Chen, X., Zhao, Y., Lan, Y., & Yue, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.980405 · Cited by 52
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
“DPP4-Is can be therefore considered as an alternative option in metformin-intolerant women with IGT or T2DM due to their safety profile and convenient administration route [146].”
BackgroundInfluentialUpdate on Animal Models of Polycystic Ovary Syndrome
Stener‐Victorin, E. (2022) · Endocrinology · doi:10.1210/endocr/bqac164 · Cited by 46
Insulin resistance, metabolic syndrome and polycystic ovaries: an intriguing conundrum
Prosperi, S., & Chiarelli, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1669716 · Cited by 72
An approach for Personalized Continuous Glucose Prediction with Regression Trees
Alexiou, S., Dritsas, E., Kocsis, O., Μουστάκας, Κ., & Fakotakis, N. (2021) · South-East Europe Design Automation, Computer Engineering, Computer Networks and Social Media Conference (SEEDA-CECNSM) · doi:10.1109/seeda-cecnsm53056.2021.9566278 · Cited by 36
Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease
Dubey, P., Reddy, S., Sharma, K., Johnson, S., Hardy, G., & Dwivedi, A. K. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02050-5 · Cited by 51
“The rate of T2DM was high even after adjustment for BMI indicating an independent association of PCOS with the risk of development of T2DM in individual studies [25, 27–29].”
Pirotta, S., Joham, A., Grieger, J. A., Tay, C. T., Bahri-Khomami, M., Lujan, M., Lim, S. S., & Moran, L. J. (2020) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1726866 · Cited by 29
Self-citationBroadening horizons: the role of ferroptosis in polycystic ovary syndrome
Wang, M., Zhang, B.-Q., Ma, S., Xu, Y. J., Zhao, D.-H., Zhang, J., Li, C.-J., Zhou, X., & Zheng, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1390013 · Cited by 37
Osibogun, O. I., Ogunmoroti, O., Kolade, O. B., Hays, A. G., Okunrintemi, V., Minhas, A., Gulati, M., & Michos, E. D. (2022) · Journal of Women s Health · doi:10.1089/jwh.2021.0608 · Cited by 28
Zhang, Y., Martin, L. J., Mustieles, V., Ghaly, M., Archer, M., Sun, Y., Torres, N., Coburn-Sanderson, A., Souter, I. C., Petrozza, J. C., et al. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.175313 · Cited by 26
Artificial intelligence in polycystic ovarian syndrome management: past, present, and future
Wang, J., Chen, R., Long, H., He, J., Tang, M., Su, M., Deng, R., Chen, Y., Ni, R., Zhao, S., et al. (2025) · La radiologia medica · doi:10.1007/s11547-025-02032-9 · Cited by 39
Pierro, F. D., Sultana, R., Eusaph, A. Z., Abrar, S., Bugti, M., Afridi, F., Farooq, U., Iqtadar, S., Ghauri, F., Makhduma, S., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1269605 · Cited by 34
Insights on the NF-κB system in polycystic ovary syndrome, attractive therapeutic targets
Tan, W., Zhang, J., Dai, F., Yang, D., Gu, R., Tang, L., Liu, H., & Cheng, Y. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04736-w · Cited by 34
Tharayil, S. P., & Shukla, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136233 · Cited by 33
Xia, Y., Wang, Y., Cui, M., & Su, D. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1050 · Cited by 23
“The presence of IR with consequent increased likelihood of further developing type II diabetes mellitus (T2D) is indeed a common finding in PCOS, with a prevalence of 50–70% (3,27).”
BackgroundGlintborg, D., Ollila, M., Møller, J. K., Pesonen, P., Persson, S., Elenis, E., Rubin, K. H., Gissler, M., Andersen, M., Poromaa, I. S., et al. (2024) · Human Reproduction · doi:10.1093/humrep/deae124 · Cited by 26
Approach to the Patient: Diagnostic Challenges in the Workup for Polycystic Ovary Syndrome
Joham, A. E., Tay, C. T., Laven, J. S. E., Louwers, Y. V., & Azziz, R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae910 · Cited by 36
Self-citationMetabolic Deregulations in Patients with Polycystic Ovary Syndrome
Jabczyk, M., Nowak, J., Jagielski, P., Hudzik, B., Kulik-Kupka, K., Włodarczyk, A., Lar, K., & Zubelewicz‐Szkodzińska, B. (2023) · Metabolites · doi:10.3390/metabo13020302 · Cited by 27
“02 per 1000 population [p < 0·001]) [33].”
Kumarendran, B., O’Reilly, M., Subramanian, A., Šumilo, D., Toulis, K. A., Gokhale, K. M., Wijeratne, C. N., Coomarasamy, A., Tahrani, A. A., Azoulay, L., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0437 · Cited by 26
Rasmussen, J., Selmer, C., Frøssing, S., Schou, M., Faber, J. O., Torp-Pedersen, C. T., Gislason, G., Køber, L., HOUGAARD, D. M., Cohen, A. S., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa050 · Cited by 26
“The impact of endogenous androgens on risk of type 2 diabetes is well established in women with established hyperandrogenism such as polycystic ovary syndrome (PCOS) [1, 2], a condition strongly associated with increased insulin resistance, but knowledge on plasma testosterone level per se as a risk factor in women wi…”
BackgroundInfluentialMetabolic Features of Women With Polycystic Ovary Syndrome in Latin America: A Systematic Review
Marchesan, L. B., Ramos, R. B., & Spritzer, P. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.759835 · Cited by 33
“In this respect, the finding of decreased insulin sensitivity in Latin American women with PCOS, as opposed to controls, is in line with current evidence from other regions (6, 15) and has been associated with low-grade chronic inflammation, linked to increasing BMI (68, 69).”
BackgroundResultAssessment of Type 2 Diabetes Risk in Young Women with Polycystic Ovary Syndrome
Livadas, S., Paparodis, R. D., Anagnostis, P. G., Gambineri, A., Bjekić-Macut, J., Petrović, T., Yıldız, B. O., Micić, D., Mastorakos, G. P., & Μacut, D. (2023) · Diagnostics · doi:10.3390/diagnostics13122067 · Cited by 24
“8 cases per 1000 PYs reported for the adult PCOS population [33].”
BackgroundMetabolic profile of women with PCOS in Brazil: a systematic review and meta-analysis
Spritzer, P. M., Ramos, R. B., Marchesan, L. B., de Oliveira, M., & Carmina, E. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00636-5 · Cited by 27
Medical Treatment and Comorbidity in Polycystic Ovary Syndrome: An Updated Review
Glintborg, D., & Andersen, M. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.02.014 · Cited by 20
“9 for type 2 diabetes in women with PCOS compared to weight matched controls [19].”
BackgroundWang, F., Dou, P., Wei, W., & Liu, P. J. (2024) · Nutrition & Diabetes · doi:10.1038/s41387-024-00263-9 · Cited by 20
“They are also at an increased risk of developing metabolic syndrome and type 2 diabetes mellitus (T2DM) [2, 3].”
BackgroundPPAR-α inhibits DHEA-induced ferroptosis in granulosa cells through upregulation of FADS2
Liu, Y., Ni, F., Huang, J., Hu, Y., Wang, J., Wang, X., Du, X., & Jiang, H. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150005 · Cited by 23
Liao, W., Su, C.-C., Lee, M.-T., Li, C.-J., Lin, C., Chiang, J., & Yen, H. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112091 · Cited by 22
Zhang, Z., Shi, C., & Wang, Z. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1279469 · Cited by 22
Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review
Monney, M., Mavromati, M., Leboulleux, S., & Gariani, K. (2025) · Endocrine Connections · doi:10.1530/ec-24-0529 · Cited by 30
“Furthermore, the relative risk of type 2 diabetes is tripled in women with PCOS compared to matched controls (15).”
Prospective Risk of Type 2 Diabetes in Normal Weight Women with Polycystic Ovary Syndrome
Glintborg, D., Kolster, N. D., Ravn, P., & Andersen, M. (2022) · Biomedicines · doi:10.3390/biomedicines10061455 · Cited by 21
“Four controlled studies reported a higher risk of T2D in lean/normal weight women with PCOS compared to controls [18,26,31,33], whereas comparable risk for T2D in PCOS and controls was reported in the remaining six studies [8,25,27,32,34,35].”
BackgroundMethodResultInfluentialLi, X., Zhang, T., Li, S., Deng, Y., Wang, L., Tao, T., Wang, S., Gu, Y., Gu, W., Hong, J., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14154 · Cited by 17
Marschalek, M., Marculescu, R., Schneeberger, C., Marschalek, J., Dewailly, D., & Ott, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1173422 · Cited by 20
“Given that insulin resistance is common in PCOS with a prevalence of 75-95% according to clamp studies (18), that the PCOS prevalence increases with obesity (19) and that the risk for insulin resistance and type 2 diabetes is higher in overweight and obese PCOS women (20), one could hypothesize that sympathetic activi…”
BackgroundWeight Management in Adolescents with Polycystic Ovary Syndrome
Moore, J. M., Waldrop, S., & Cree‐Green, M. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00437-x · Cited by 23
Liu, C., Zhang, L., Zheng, W., Liang, X., Zhang, L., Tian, Z., & Li, G. (2021) · Obesity Facts · doi:10.1159/000514931 · Cited by 22
Melin, J. M., Forslund, M., Alesi, S. J., Piltonen, T., Romualdi, D., Spritzer, P. M., Tay, C. T., Pena, A. S., Witchel, S. F., Mousa, A., et al. (2024) · Clinical Endocrinology · doi:10.1111/cen.14983 · Cited by 16
Self-citationNg, N. Y. H., Wu, H., Lau, E. S. H., Zhang, X., Yang, A., Tsang, A. Y. T., Yau, T., Kong, A. P. S., Ng, K., Chung, J. P. W., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110640 · Cited by 19
The Role of the Mediterranean Diet in Assisted Reproduction: A Literature Review
Baroutis, D., Kalampokas, T., Katsianou, E., Psarris, A., Daskalakis, G., Panoulis, K. P. C., & Eleftheriades, M. I. (2024) · Nutrients · doi:10.3390/nu16162807 · Cited by 19
“…conflicting and do not demonstrate a clear and catalytic effect of the Mediterranean Diet on assisted reproductive techniques [8,9] and their outcomes, it is a fact that the Mediterranean Diet is the most popular beneficial dietary pattern for human health and fertility promotion [5,13,37,54,55].”
BackgroundZhu, M., Xu, Y., Li, C., Lu, Z., Bi, K., Wang, K., Guo, P., Jiang, H., & Cao, Y. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00861-7 · Cited by 16
Stener‐Victorin, E., Eriksson, G., Shrestha, M. M., Paris, V. R., Lu, H., Banks, J. L., Samad, M., Perian, C., Jude, B., Engman, V., et al. (2023) · eLife · doi:10.7554/elife.87592 · Cited by 22
“More than 50% of women with PCOS are overweight or obese, and obesity worsens all symptoms, including insulin resistance ( Kakoly et al., 2019 ; Barber and Franks, 2021 ).”
Changes in Metabolic Profile in the Women with a History of PCOS—A Long-Term Follow-Up Study
Jacewicz‐Święcka, M., & Kowalska, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103367 · Cited by 21
“Obesity synergistically with PCOS increases IR and hyperinsulinaemia [20,21] and affects worse metabolic prognosis [21,22].”
BackgroundThe Risks of Polycystic Ovary Syndrome and Diabetes Vary by Ethnic Subgroup Among Young Asian Women
Guo, L., Gordon, N. P., Chandra, M., Dayo, O. M., & Lo, J. C.-M. (2021) · Diabetes Care · doi:10.2337/dc21-0373 · Cited by 15
Pei, Z., Lu, W., Feng, Y., Xu, C., & Hsueh, A. J. W. (2022) · Human Reproduction · doi:10.1093/humrep/deac156 · Cited by 15
Dietary Total Antioxidant Capacity and Risk of Polycystic Ovary Syndrome: A Case-Control Study.
Shoaibinobarian, N., Eslamian, G., Noormohammadi, M., Malek, S., Rouhani, S., & Mirmohammadali, S. N. (2022) · PubMed Central · doi:10.22074/ijfs.2021.526579.1107 · Cited by 26
“Polycystic ovary syndrome (PCOS) is a common gynecological endocrinopathy that affects 8-13% of women in the reproductive age (1).”
BackgroundLi, X., Xiao, H., Ma, Y., Zhou, Z., & Chen, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.905716 · Cited by 15
“It partly explains why overweight or obese women with PCOS are more likely to experience T2D (Kakoly et al., 2019).”
BackgroundEvidence of positive selection of genetic variants associated with PCOS
Yu, Z., Li, Y., Zhao, S., Liu, F., Zhao, H., & Chen, Z. (2023) · Human Reproduction · doi:10.1093/humrep/dead106 · Cited by 12
Mohammed, S., Sundaram, V., & Zyuzikov, N. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00774-4 · Cited by 13
“However, complex interactions between genetic, behavioural, and environmental factors play critical roles in the development of PCOS and subsequent therapeutic options (Kakoly et al., 2019).”
BackgroundNazeer, K., Lone, N. M., Sadique, S., Sultan, S., Eupash, A. Z., & Riaz, S. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.03.014 · Cited by 9
Kerbus, R. I., Decourt, C., Inglis, M. A., Campbell, R. E., & Anderson, G. M. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13370 · Cited by 13
Ding, N., Yue, R., Wang, L., & Yang, H. (2020) · Medicine · doi:10.1097/md.0000000000022982 · Cited by 9
“Its main symptoms include syndromes as oligo/anovulation, hyperandrogenism, hirsutism, obesity, and polycystic ovaries on ultrasonogram.([2]) The potential pathogenesis of PCOS is related to Insulin resistance (IR) and compensatory hyperinsulinemia.”
BackgroundKim, J., Kim, O., Jung, H., Pang, Y., & Dan, H. (2021) · Health Care For Women International · doi:10.1080/07399332.2021.1939348 · Cited by 11
“In addition, several researchers have revealed long-term complications of PCOS such as cardiovascular disease (Feldman et al., 2017) or type II diabetes (Kakoly et al., 2019).”
BackgroundFeatures of circumference sizes in women of different constitutional groups
Nuruev, M., Sakibaev, K. S., Dzholdosheva, G. T., et al. (2022) · Clinical Physiology and Functional Imaging · doi:10.1111/cpf.12791 · Cited by 9
“The constitutional groups of people of different ages, genders and nationalities were investigated (Kakoly et al., 2019; Marchio et al., 2019).”
BackgroundJanež, A., Herman, R., Poredoš, P., Mikhailidis, D. P., Blinc, A., Šabović, M., Studen, K. B., Jezovnik, M. K., Schernthaner, G.-H., Anagnostis, P. G., et al. (2023) · Current Vascular Pharmacology · doi:10.2174/0115701611269146230920073301 · Cited by 11
Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical Implications
López‐Alarcón, M., Vital-Reyes, V. S., Almeida‐Gutiérrez, E., Maldonado‐Hernández, J., Flores, S., Domínguez-Salgado, J. M., Vite-Bautista, J., Cruz-Martínez, D., Barradas-Vázquez, A. S., & Z’Cruz-López, R. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13091319 · Cited by 12
“Scientific evidence suggests that androgen excess plays a critical role in the pathophysiology of metabolic disturbances [3,4], but it is unclear whether these disturbances are related to obesity, as PCOS often coexists with this phenotype.”
Backgroundvan Bree, B. E., van der Heijden, D. M. B., van Golde, R. J. T., Brouwers, M. C. G. J., Spaanderman, M. E. A., & Valkenburg, O. (2025) · Gynecological Endocrinology · doi:10.1080/09513590.2025.2500462 · Cited by 8
“Epidemiological studies have shown that women with PCOS have an increased risk on DMII that is independent of BMI [17].”
Das polyzystische Ovarsyndrom als genderspezifischer kardiometabolischer Risikofaktor
van Baal, L., & Tan, S. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01529-7 · Cited by 8
Natural History of Polycystic Ovary Syndrome and New Advances in the Epidemiology
Piltonen, T., Arffman, R. K., & Joham, A. E. (2021) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1735211 · Cited by 7
Self-citationJafari, K., Tajik, N., Moini, A., SeyedAlinaghi, S., & Abiri, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-01287-6 · Cited by 7
“…mass index (BMI) is not only directly linked to infertility 14–17 but also associates with alterations in lipid profile and glucose metabolism, including abnormal levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), and fasting blood sugar (FBS) 7,8,18,19 .”
Ware, M. A., Kaar, J. L., Behn, C. D., Bartlette, K., Carreau, A., Lopez‐Paniagua, D., Scherzinger, A. L., Xie, D., Rahat, H., Garcia‐Reyes, Y., et al. (2021) · Obesity · doi:10.1002/oby.23317 · Cited by 7
“For example, women with PCOS and obesity are eight times more likely to be diagnosed with type 2 diabetes (T2D) compared with age- and BMI- matched control individuals (5).”
BackgroundPolycystic Ovary Syndrome in Adolescence
Joham, A. E., & Peña, A. S. (2022) · Seminars in Reproductive Medicine · doi:10.1055/s-0042-1757138 · Cited by 13
Self-citationHuang, Y., & Zhang, X. (2023) · Medicine · doi:10.1097/md.0000000000035403 · Cited by 13
“[2] Most PCOS patients present with menstrual disorders, hyperandrogenism, obesity, and insulin resistance.[3,4] The Rotterdam diagnostic criteria stipulates that any 2 of the following requirements must be met for the diagnosis of PCOS: oligogenesis or anovulation; clinical and/or biochemical detection of hyperandrog…”
BackgroundAnosike, C., Okoye, C. O., Isiogugu, N. O., et al. (2025) · BMC Medical Education · doi:10.1186/s12909-025-07373-7 · Cited by 5
“Hence, the risk of PCOS is known to be higher in women with a family history of PCOS or type 2 diabetes mellitus (T2DM) [8, 9], thus suggesting that PCOS has a familial predisposition.”
Roney, M., Issahaku, A. R., Hamim, S. M. I., Wilhelm, A., & Aluwi, M. F. F. M. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10119-z · Cited by 6
“Epidemiological studies reveal that over half of women with PCOS are diagnosed with T2DM by age 40, emphasizing the urgency of early detection and intervention [10].”
Polycystic ovary syndrome in pediatric obesity and diabetes
DONDI, E., TUFANO, M., VIGONE, M. C., LUCACCIONI, L., POZZOBON, G., Ubertini, G., Mozzillo, E., & Delvecchio, M. (2021) · Minerva Pediatrics · doi:10.23736/s2724-5276.21.06542-3 · Cited by 8
Cao, S., Jones, M., Tooth, L. R., & Mishra, G. D. (2021) · Archives of Women s Mental Health · doi:10.1007/s00737-021-01182-9 · Cited by 5
Shafqat, S., Anwar, Z., Rasool, R. U., Javaid, Q., & Ahmad, H. F. (2023) · Qeios · doi:10.32388/67kz7s.2 · Cited by 6
Effects of polycystic ovary syndrome on liver, heart, muscle, and pancreatic-related diseases
Li, B., Li, Y., Li, X., Yu, Z., Yu, J., Shao, Y., Li, T., Sun, S., Zhou, L., Yao, R., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1776584 · Cited by 5
“…the release of pro-in fl ammatory mediators, triggering the opening of the mitochondrial permeability transition pore that leads to cellular apoptosis, and stimulating pancreatic stellate cells, which in turn contribute to fi brosis and microthrombus formation detrimental to acinar cells (92, 93).”
Jiang, H., Guo, Y., Chen, L., Shi, H., Huang, N., Chi, H., Yang, R. J., Long, X., & Qiao, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113863 · Cited by 3
“Specifically, the incidence of T2DM is four-fold higher in women with PCOS compared to those without PCOS in a cohort study based on the Australian Longitudinal Study on Women’s Health (ALSWH) database [37].”
Background
Metadata
- Authors
- Kakoly, N. S., Earnest, A., Teede, H. J., Moran, L. J., & Joham, A. E.
- Affiliations
- Monash University (AU)
- Monash Health (AU)
- Corresponding author
- Joham, Anju E.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-01-31
- Volume
- 42
- Issue
- 4
- Pages
- 560-567
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2911538911
- Cited by
- 174
- References
- 32
- Citations by year
- 2026: 11 · 2025: 31 · 2024: 26 · 2023: 36 · 2022: 18 · 2021: 32 · 2020: 13 · 2019: 7
- FWCI
- 16.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Keywords
- polycystic ovary syndrome, type 2 diabetes, obesity, diabetes incidence, lean women, body mass index, diabetes screening, women's health, risk factors
- MeSH terms
- Adolescent, Adult, Australia, Body Weight, Diabetes Mellitus, Type 2, Female, Humans, Longitudinal Studies, Obesity, Polycystic Ovary Syndrome, Risk, Cohort Studies, Body Mass Index, Incidence, Overweight, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.